These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

359 related items for PubMed ID: 24148817

  • 1. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
    Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, Williams M, Wright C, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, Brahmbhatt H, MacDiarmid JA, van Zandwijk N.
    Ann Oncol; 2013 Dec; 24(12):3128-35. PubMed ID: 24148817
    [Abstract] [Full Text] [Related]

  • 2. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
    Cioce M, Ganci F, Canu V, Sacconi A, Mori F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, Carosi MA, Blandino R, Panebianco V, Facciolo F, Visca P, Volinia S, Muti P, Strano S, Croce CM, Pass HI, Blandino G.
    Oncogene; 2014 Nov 13; 33(46):5319-31. PubMed ID: 24240684
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
    Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F.
    Chemotherapy; 2008 Nov 13; 54(3):166-75. PubMed ID: 18560222
    [Abstract] [Full Text] [Related]

  • 7. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.
    J Thorac Oncol; 2017 Sep 13; 12(9):1421-1433. PubMed ID: 28629895
    [Abstract] [Full Text] [Related]

  • 8. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RC, Reid G.
    Mol Cancer; 2016 Jun 01; 15(1):44. PubMed ID: 27245839
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M, Trapani D, Ravn J, Sørensen JB, Andersen CB, Grauslund M, Santoni-Rugiu E.
    Anticancer Res; 2015 Nov 01; 35(11):6223-9. PubMed ID: 26504055
    [Abstract] [Full Text] [Related]

  • 15. MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
    Singh A, Bhattacharyya N, Srivastava A, Pruett N, Ripley RT, Schrump DS, Hoang CD.
    Mol Ther; 2019 Sep 04; 27(9):1665-1680. PubMed ID: 31227395
    [Abstract] [Full Text] [Related]

  • 16. miR-1 induces growth arrest and apoptosis in malignant mesothelioma.
    Xu Y, Zheng M, Merritt RE, Shrager JB, Wakelee HA, Kratzke RA, Hoang CD.
    Chest; 2013 Nov 04; 144(5):1632-1643. PubMed ID: 23828229
    [Abstract] [Full Text] [Related]

  • 17. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T, Gesmundo I, Audrito V, Vitale N, Silvagno F, Musuraca C, Righi L, Libener R, Riganti C, Bironzo P, Deaglio S, Papotti M, Cai R, Sha W, Ghigo E, Schally AV, Granata R.
    Proc Natl Acad Sci U S A; 2019 Feb 05; 116(6):2226-2231. PubMed ID: 30659154
    [Abstract] [Full Text] [Related]

  • 18. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
    Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T.
    Int J Cancer; 2013 Jan 15; 132(2):459-71. PubMed ID: 22532243
    [Abstract] [Full Text] [Related]

  • 19. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
    Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G.
    Int J Oncol; 2010 Aug 15; 37(2):437-44. PubMed ID: 20596671
    [Abstract] [Full Text] [Related]

  • 20. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W.
    Mol Cancer Ther; 2016 Oct 15; 15(10):2357-2369. PubMed ID: 27512118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.